Keynote Speakers Announced for 2018 ISPE Annual Meeting & Expo
Keynote speakers where announced for the 2018 ISPE Annual Meeting & Expo. Taking place in Philadelphia, Pennsylvania, November 4–7, keynote addresses will showcase global pharmaceutical industry leaders offering compelling and enlightening presentations on industry-critical technical developments.
Keynote Speakers:
As Novo Nordisk moves toward a regulatory submission of its new oral semaglutide, Lars will offer his perspective on how to strive for leadership in diabetes management and simultaneously provide groundbreaking innovation in manufacturing.
Pharmaceutical manufacturing and supply organizations respond to high expectations from R&D and commercial organizations, regulators, and shareholders. Kirsten will discuss how Pfizer’s global supply team manages these expectations, emerging technologies, and complex supply chains to deliver important medicines to patients now and in the future.
Development and delivery of gene and cell therapies in clinical and commercial settings present new challenges for biotech companies and their partners, and new opportunities to innovate at all levels, including manufacturing. Nick’s presentation will delve into the ways that companies can leverage in-house capabilities and strategic partnerships to deliver cutting edge therapies to patients with genetic diseases and cancer, and what’s still needed in order to make these therapies widely available.
The pharmaceutical industry’s work has a major impact on the health and lives of patients who benefit from today’s medicines. Becky will share her personal journey of living with diabetes and the possibilities that emerging therapies offer to enhance the lives of other patients.
The 2018 ISPE Annual Meeting & Expo delivers a broad spectrum of technical education for multiple levels of expertise across six tracks, five technical workshops, and more than 50 education sessions. In addition, an extensive Expo will showcase more than 300 companies offering advanced technologies and services.
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...